Navigation Links
Doctors should stop prescribing antibiotics for the common cold, review advises

Antibiotics should not be prescribed to patients with the common cold because there is scant evidence they stop other infections, and the benefits do not outweigh the risks, according to a new systematic review of current evidence.

"Antibiotics appear to have no benefit in the treatment of acute upper respiratory tract infections," conclude Dr. Bruce Arroll and Dr. Timothy Kenealy of the University of Auckland, New Zealand. "The implications for practice are that prescription of antibiotics should not be given in the first instance as they will not improve the symptoms and adult patients will get adverse effects."

In addition to the side effects, mainly diarrhea, "overuse can increase levels of antibiotic resistance in the community," the review advises.

Colds are caused by viruses and not bacteria, upon which antibiotics act, yet, says Arroll, "There is evidence of high usage of antibiotics for the common cold in spite of doubts about the efficacy of such therapy." The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic. Arroll reviewed 12 trials that included more than 1,900 patients with symptoms lasting for seven days or less or with colds that included runny noses with colored discharge for 10 days or less. The patients had been given either antibiotics or placebo. "People receiving antibiotics did no better in terms of lack of cure or persistence of symptoms than those on placebo," Arroll says.

The goal of the study, according to the authors, was to determine if antibiotics reduce general cold symptoms such as sneezing, inflammation of the nose and throat; if antibiotics have any effect on pus-like nasal discharge; and if antibiotics have significant side eff ects in people with colds.

Although there may be some benefit of using antibiotics to treat the runny nose with colored discharge (acute purulent rhinitis), "their routine use is not recommended," the review says.

Colds are the most common reason for new patient visits at general practioners' offices, the review reports, and although the antibiotics do not work for that purpose, it is the second most common reason doctors prescribe them, Arroll writes.

"Physicians prescribe antibiotics in these cases out of habit and/or because they do not agree with the evidence," says Dr. Arroll. "Antibiotics do work for a minority of patients with purulent rhinitis, one out of five, so they may generalize this experience to their wider patient group."

Dr. Norman H. Edelman, chief medical officer for the American Lung Association, says, "There is no simple answer as to why providers do this. Some physicians may want to prevent complications of bacterial infections, which do occur. Some may be yielding to pressure from patients." But he says "this practice is on the decline as the public becomes more sophisticated about health issues."

Dr. Arroll says that patients are not doing themselves any favors looking for a "quick fix" in pressuring their providers to prescribe antibiotics for colds. "Patients will get a quicker fix if they take decongestants such as pseudoephedrine (Sudafed)," he says.


'"/>

Source:Center for the Advancement of Health


Related biology news :

1. Doctors closer to using gene analysis to help trauma patients
2. New Discovery May Help Doctors Treat Infertility
3. Tsunami-damaged coral reefs should be left to recover naturally, say scientists
4. Newest HIV drugs should be used with FUZEON(R)
5. Discovery of an American salamander where it shouldnt be: Korea
6. Scientists discover stem cell origin of neck and shoulders
7. WCS says avian flu prevention should focus on farms, markets
8. Brains response to visual stimuli helps us to focus on what we should see, rather than all there is to see
9. Tsunami + 1 year: Reviving exhausted fisheries should trump replacing boats, gear, experts say
10. Minimal genome should be twice the size, study shows
11. How the US drug safety system should be changed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a ... its financial results for the fourth quarter and fiscal year ... Total sales in the fourth quarter ... by 13.6% in USD terms to $77.6 million from $68.3 ... Gross profit increased by 13.3% to $46.8 million from $41.3 ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
Breaking Biology Technology: